{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:32:34Z","timestamp":1791498754922,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>R-CHOP with or without radiotherapy is the standard treatment for limited-stage diffuse large B-cell lymphoma (DLBCL). To prevent overtreatment, we assessed whether four cycles of CHOP plus six applications of rituximab was adequate with negative interim PET\/CT and the role of consolidation radiotherapy specifically for patients with Waldeyer\u2019s ring DLBCL. One hundred and twenty-nine patients with limited-stage DLBCL were enrolled in this open-label, nonrandomized, single-arm, phase 2 clinical trial (NCT01804127).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All patients were initially treated with 4\u2009cycles of R-CHOP and underwent interim PET\/CT. Patients with negative PET\/CT (Deauville scores 1\u20132) received 2 additional cycles of rituximab monotherapy, unless they had any risk factors (primary mediastinal large B-cell lymphoma, extranodal primary or bulky disease). Otherwise, patients received another 2\u2009cycles of R-CHOP. Patients with partial response on interim PET\/CT received another 4\u2009cycles of R-CHOP. No radiotherapy was conducted in Waldeyer\u2019s ring DLBCL patients with negative PET\/CT. The primary endpoint was 3-year progression-free survival (PFS). Overall survival (OS) in this study was compared with those from a historical study (NCT 00854568159).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred fifteen interim PET\/CT scans (89.1%) were negative after 4\u2009cycles of R-CHOP. An elevated lactate dehydrogenase level was significantly associated with positive interim PET\/CT (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). A trend of inferior outcome was observed in patients with positive interim PET\/CT in terms of 3-year PFS (78.6% vs. 91.9%, <jats:italic>P<\/jats:italic>\u2009=\u20090.24) and 3-year OS (85.7% vs. 95.6%, <jats:italic>P<\/jats:italic>\u2009=\u20090.16). There were no PFS or OS differences found between patients treated with 4R-CHOP+2R and those treated with 6R-CHOP from a historical control study. Patients with Waldeyer\u2019s ring DLBCL and negative interim PET\/CT achieved a 3-year PFS of 87.2% and a 3-year OS of 89.7%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results suggested that for interim PET\/CT-negative patients without risk factors, the extra 2\u2009cycles of CHOP might be omitted, and radiotherapy might also be omitted in patients with Waldeyer\u2019s ring DLBCL without compromising the efficacy. These results need to be confirmed in a randomized study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link>,\u2002<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01804127?term=01804127&amp;rank=1\">NCT 01804127<\/jats:ext-link>. Date of first registration: 05\/03\/2013.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09486-4","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T11:29:04Z","timestamp":1649849344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET\/CT: an analysis of a prospective trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Jia","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuguang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junning","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6636-3056","authenticated-orcid":false,"given":"Fangfang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"issue":"5 Suppl","key":"9486_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.6004\/jnccn.2014.0193","volume":"12","author":"AD Zelenetz","year":"2014","unstructured":"Zelenetz AD. Guidelines for NHL: updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia. J Natl Compr Cancer Netw. 2014;12(5 Suppl):797\u2013800.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"8","key":"9486_CR2","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol. 1998;16(8):2780\u201395.","journal-title":"J Clin Oncol"},{"issue":"14","key":"9486_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002\u20136.","journal-title":"N Engl J Med"},{"issue":"4","key":"9486_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med"},{"issue":"12","key":"9486_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes Des Lymphomes De l'Adulte. Blood. 2010;116(12):2040\u20135.","journal-title":"Blood."},{"issue":"2","key":"9486_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105\u201316.","journal-title":"Lancet Oncol."},{"issue":"5","key":"9486_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 2006;7(5):379\u201391.","journal-title":"Lancet Oncol."},{"issue":"11","key":"9486_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group. Lancet Oncol. 2011;12(11):1013\u201322.","journal-title":"Lancet Oncol."},{"issue":"12","key":"9486_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.clml.2016.08.020","volume":"16","author":"M Bolshinsky","year":"2016","unstructured":"Bolshinsky M, Nabhan C. Interim PET scans in diffuse large B-cell lymphoma: is it ready for prime time? Clin Lymphoma Myeloma Leuk. 2016;16(12):655\u201361.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"9486_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","volume":"14","author":"R Delarue","year":"2013","unstructured":"Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14(6):525\u201333.","journal-title":"Lancet Oncol"},{"issue":"10216","key":"9486_CR11","first-page":"2271","volume":"394","author":"V Poeschel","year":"2019","unstructured":"Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with Favourable prognosis (FLYER): a randomised, phase 3. Non-Inferiority Trial Lancet. 2019;394(10216):2271\u201381.","journal-title":"Non-Inferiority Trial Lancet"},{"issue":"4","key":"9486_CR12","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","volume":"106","author":"C Haioun","year":"2005","unstructured":"Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106(4):1376\u201381.","journal-title":"Blood."},{"issue":"3","key":"9486_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/annonc\/mdn671","volume":"20","author":"J Dupuis","year":"2009","unstructured":"Dupuis J, Itti E, Rahmouni A, Hemery F, Gisselbrecht C, Lin C, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18Fluorodeoxyglucose positron emission tomography to the international workshop criteria. Ann Oncol. 2009;20(3):503\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"9486_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.108.057703","volume":"50","author":"E Itti","year":"2009","unstructured":"Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50(4):527\u201333.","journal-title":"J Nucl Med"},{"issue":"9","key":"9486_CR15","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.ejca.2010.12.027","volume":"47","author":"DH Yang","year":"2011","unstructured":"Yang DH, Min JJ, Song HC, Jeong YY, Chung WK, Bae SY, et al. Prognostic significance of interim (1)(8)F-FDG PET\/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer. 2011;47(9):1312\u20138.","journal-title":"Eur J Cancer"},{"issue":"2","key":"9486_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1200\/JCO.2011.38.2648","volume":"30","author":"V Safar","year":"2012","unstructured":"Safar V, Dupuis J, Itti E, Jardin F, Fruchart C, Bardet S, et al. Interim [18F]Fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol. 2012;30(2):184\u201390.","journal-title":"J Clin Oncol"},{"issue":"5","key":"9486_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/PPO.0b013e31826c5907","volume":"18","author":"LH Sehn","year":"2012","unstructured":"Sehn LH. Chemotherapy alone for localized diffuse large B-cell lymphoma. Cancer J. 2012;18(5):421\u20136.","journal-title":"Cancer J"},{"key":"9486_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.leukres.2018.09.011","volume":"74","author":"C Li","year":"2018","unstructured":"Li C, Ma X, Pan Z, Lv F, Xia Z, Xue K, et al. Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP Immunochemotherapy. Leuk Res. 2018;74:80\u20135.","journal-title":"Leuk Res"},{"issue":"27","key":"9486_CR19","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"22","key":"9486_CR20","doi-asserted-by":"publisher","first-page":"32519","DOI":"10.18632\/oncotarget.8685","volume":"7","author":"K Xue","year":"2016","unstructured":"Xue K, Gu JJ, Zhang Q, Liu X, Wang J, Li XQ, et al. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: results from a randomized prospective clinical trial. Oncotarget. 2016;7(22):32519\u201331.","journal-title":"Oncotarget."},{"issue":"23","key":"9486_CR21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2016-05-672196","volume":"129","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Casasnovas RO. Interim PET-driven strategy in De novo diffuse large B-cell lymphoma: do we trust the driver? Blood. 2017;129(23):3059\u201370.","journal-title":"Blood."},{"issue":"9","key":"9486_CR22","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.3109\/10428194.2015.1007506","volume":"56","author":"SF Huntington","year":"2015","unstructured":"Huntington SF, Nasta SD, Schuster SJ, Doshi JA, Svoboda J. Utility of interim and end-of-treatment [(18)F]-Fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(9):2579\u201384.","journal-title":"Leuk Lymphoma."},{"issue":"4","key":"9486_CR23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00277-012-1640-x","volume":"92","author":"DH Yang","year":"2013","unstructured":"Yang DH, Ahn JS, Byun BH, Min JJ, Kweon SS, Chae YS, et al. Interim PET\/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Ann Hematol. 2013;92(4):471\u20139.","journal-title":"Ann Hematol"},{"issue":"9","key":"9486_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2016.1277384","volume":"58","author":"Y Fan","year":"2017","unstructured":"Fan Y, Zhang Y, Yang Z, Ying Z, Zhou N, Liu C, et al. Evaluating early interim Fluorine-18 Fluorodeoxyglucose positron emission tomography\/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2017;58(9):1\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"9486_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/COC.0b013e3181841f42","volume":"32","author":"DT Chang","year":"2009","unstructured":"Chang DT, Amdur RJ, Pacholke H, Mendenhall NP, Morris CG, Byer GA, et al. Xerostomia in long-term survivors of aggressive non-Hodgkin's lymphoma of Waldeyer's ring: a potential role for parotid-sparing techniques? Am J Clin Oncol. 2009;32(2):145\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"9486_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ijrobp.2016.05.023","volume":"96","author":"YG Xu","year":"2016","unstructured":"Xu YG, Qi SN, Wang SL, Liu YP, Wang WH, Jin J, et al. Dosimetric and clinical outcomes with intensity modulated radiation therapy after chemotherapy for patients with early-stage diffuse large B-cell lymphoma of Waldeyer ring. Int J Radiat Oncol Biol Phys. 2016;96(2):379\u201386.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"9486_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","volume":"118","author":"RO Casasnovas","year":"2011","unstructured":"Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118(1):37\u201343.","journal-title":"Blood."},{"issue":"12","key":"9486_CR28","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1080\/10428190600942959","volume":"47","author":"C Fruchart","year":"2006","unstructured":"Fruchart C, Reman O, Le Stang N, Musafiri D, Cheze S, Macro M, et al. Prognostic value of early 18 Fluorodeoxyglucose positron emission tomography and Gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study. Leuk Lymphoma. 2006;47(12):2547\u201357.","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"9486_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/annonc\/mdn629","volume":"20","author":"HS Han","year":"2009","unstructured":"Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20(2):309\u201318.","journal-title":"Ann Oncol"},{"issue":"7","key":"9486_CR30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00277-010-1135-6","volume":"90","author":"C Yoo","year":"2011","unstructured":"Yoo C, Lee DH, Kim JE, Jo J, Yoon DH, Sohn BS, et al. Limited role of interim PET\/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol. 2011;90(7):797\u2013802.","journal-title":"Ann Hematol"},{"issue":"8","key":"9486_CR31","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2967\/jnumed.120.255034","volume":"62","author":"L Kurch","year":"2021","unstructured":"Kurch L, Huttmann A, Georgi TW, Rekowski J, Sabri O, Schmitz C, et al. Interim PET in diffuse large B-cell lymphoma. J Nucl Med. 2021;62(8):1068\u201374.","journal-title":"J Nucl Med"},{"issue":"9","key":"9486_CR32","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","volume":"5","author":"JJ Eertink","year":"2021","unstructured":"Eertink JJ, Burggraaff CN, Heymans MW, Duhrsen U, Huttmann A, Schmitz C, et al. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Adv. 2021;5(9):2375\u201384.","journal-title":"Blood Adv"},{"issue":"1","key":"9486_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2967\/jnumed.120.244145","volume":"62","author":"J Rekowski","year":"2021","unstructured":"Rekowski J, Huttmann A, Schmitz C, Muller SP, Kurch L, Kotzerke J, et al. Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: comparison of the Deauville 5-point scale and the DeltaSUVmax method. J Nucl Med. 2021;62(1):37\u201342.","journal-title":"J Nucl Med"},{"issue":"3","key":"9486_CR34","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/bjh.16875","volume":"192","author":"NG Mikhaeel","year":"2021","unstructured":"Mikhaeel NG, Cunningham D, Counsell N, McMillan A, Radford JA, Ardeshna KM, et al. FDG-PET\/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study. Br J Haematol. 2021;192(3):504\u201313.","journal-title":"Br J Haematol"},{"issue":"5","key":"9486_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09486-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T08:03:12Z","timestamp":1649923392000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09486-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9486"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09486-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,13]]},"assertion":[{"value":"7 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical standards of the Declaration of Helsinki and was approved by the Ethics Committee of Fudan University Shanghai Cancer Center. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"403"}}